Evidence map›Paper›PMID 35485698›Full record

ArticleAsian Pacific journal of cancer prevention : APJCP2022

The Impact of Direct-Acting Antiviral Agents on Cytomegalovirus Reactivation in Chronic Hepatitis C Infection.

Reham M Dawood, Ahmed A Gomaa, Mai Abd El Meguid, Essam A Hassan, Ghada M Salum, Hany Mahmoud Fares, Mostafa K El Awady, Eman M Fares, Gamal Esmat

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Asian Pacific journal of cancer prevention : APJCP, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 57% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Reham M DawoodDepartment of Microbial Biotechnology, Biotechnology Research Institute, National Research Centre, 33 EL Bohouth St., Dokki, Giza, Egypt.
Ahmed A GomaaDepartment of Tropical Medicine, Faculty of Medicine, Fayoum University, Egypt.
Mai Abd El MeguidDepartment of Microbial Biotechnology, Biotechnology Research Institute, National Research Centre, 33 EL Bohouth St., Dokki, Giza, Egypt.
Essam A HassanDepartment of Tropical Medicine, Faculty of Medicine, Fayoum University, Egypt.
Ghada M SalumDepartment of Microbial Biotechnology, Biotechnology Research Institute, National Research Centre, 33 EL Bohouth St., Dokki, Giza, Egypt.
Hany Mahmoud FaresDepartment of Physical Therapy for Internal Medicine and Surgery, Faculty of Physical Therapy, Ahram Canadian University, Egypt.
Mostafa K El AwadyDepartment of Microbial Biotechnology, Biotechnology Research Institute, National Research Centre, 33 EL Bohouth St., Dokki, Giza, Egypt.
Eman M FaresDepartment of Tropical Medicine, Faculty of Medicine, Fayoum University, Egypt.
Gamal EsmatDepartment of Endemic Medicine and Hepatogastroenterology, Faculty of Medicine, Cairo University, Cairo, Egypt.
Cairo University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe co-infection of HCV/CMV may accelerate the progression of liver diseases and worsen responsiveness to IFN treatment. The Direct-acting antiviral agents (DAAs), currently approved therapy for HCV, may cause a transient change in immune status, favoring the reactivation of other viruses. The current study aims to evaluate the impact of DAAs treatment on the reactivation of latent CMV in HCV patients.

methodsThe serological IgG, IgM Abs against CMV were detected by ELISA on192 HCV patients. The seronegative CMV IgM patients received (sofosbuvir/daclatasvir) regimen, then the CMV reactivation was examined by measuring the CMV IgM by ELISA and CMV DNA by real-time PCR.

resultsThe serological data revealed that all patients were positive for CMV IgG (100%) while (64%) patients were positive for CMV IgM. The seronegative CMV IgM (36%) received the DAAs protocol. The sustained virological response was monitored by measuring the HCV RNA viremia in the patient sera. The serological data revealed that 28.6% of patients had a reactivation of CMV, while 18.5% of patients had detectable CMV DNA viremia. Moreover, there was a significant improvement in liver function as well as a decrease in FIB-4 and APRI scores at EOT. SVR was reached 97.4% among the total studied patients (N= 192).

conclusionCMV co-infection has no impact on the response rate to DAAs. However, the CMV reactivation might have occurred after the complete eradication of HCV by DAAs.

Indexed as

CoinfectionCytomegalovirus InfectionsGraft vs Host DiseaseHepatitis CHepatitis C, ChronicAntiviral AgentsCytomegalovirusHumansImmunoglobulin GImmunoglobulin MViremiaAntiviral AgentsImmunoglobulin GImmunoglobulin MDirect-acting antiviralHepatitis C VirusHerpes virusReactivation

Identifiers

PMID35485698
PMCPMC9375591
OpenAlexW4225146416

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.